Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma

Completed · Phase 2

Conditions studied: Malignant Mesothelioma

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine and epirubicin in treating patients who have malignant mesothelioma.

Key facts

Study ID
NCT00017186
Run by
Alliance for Clinical Trials in Oncology
People needed
69
Starts
2001-07-01
Expected to finish
2008-05-01
Last updated by the study team
2016-12-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.